Investigating the impact of SGLT2 Inhibitors on Cardiovascular Outcomes  in Patients with Type 2 Diabetes

Authors

  • Dr. Hassaan Ahmad Rehman Medical College, Peshawar, Pakistan Author
  • Dr. Sana Saleem Khyber Medical College, Peshawar, Pakistan Author
  • Dr. Himayatulhaq Tahiri Bacha Khan Medical College, Mardan, Pakistan Author https://orcid.org/0009-0003-3222-1705
  • Dr. Sara Nisar Woman Medical and Dental Collage, Abbottabad, Pakistan Author
  • Dr. Safi Ullah Khyber Medical College, Peshawar, Pakistan Author
  • Dr. Musaddiq Bilal Khyber Medical College, Peshawar, Pakistan Author

DOI:

https://doi.org/10.62497/IRABCS.2024.40

Keywords:

type 2 diabetes mellitus, SGLT2 inhibitors, cardiovascular outcomes, retrospective cohort study , cardiovascular risk

Abstract

Background: A major cardiovascular risk is associated with type 2 diabetes mellitus (T2DM), hence efficient treatment approaches are required to reduce negative effects. Beyond just controlling blood sugar, sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown promise as cardiovascular medicines.
Methodology: March 2023–February 2024 saw the conduct of a retrospective cohort research at Hayatabad Medical Complex in Pakistan. The study included 58 patients with T2DM, assessing cardiovascular outcomes among those treated with and without SGLT2 inhibitors. Data on baseline characteristics, medication history, and cardiovascular events were analyzed, with multivariable regression to assess associations.
Results: Out of the total of sixty-eight patients, thirty were using SGLT2 inhibitors. Compared to the group of non-SGLT2 inhibitors, the SGLT2 inhibitor group had a decreased occurrence of cardiovascular events (13.3% vs. 28.6%, p = 0.041). The study found a significant association between the reduction of cardiovascular risk and the usage of SGLT2 inhibitors (adjusted odds ratio: 0.41, 95% confidence interval: 0.18–0.92, p = 0.032) based on multivariable regression analysis.
Conclusion: Consistent with previous research, our results show that SGLT2 inhibitors have beneficial effects on the cardiovascular system in people with type 2 diabetes. If they are a component of all-encompassing treatment plans for type 2 diabetics, SGLT2 inhibitors may even with research limitations enhance cardiovascular outcomes. Validating these results and delving further into the underlying processes will need prospective research.

Downloads

Download data is not yet available.

References

⦁ Starr JA, Pinner NA, Lisenby KM, Osmonson A. Impact of SGLT2 inhibitors

on cardiovascular outcomes in patients with heart failure with reduced

ejection fraction. Pharmacotherapy: The Journal of Human Pharmacology

and Drug Therapy. 2021 Jun;41(6):526-36.

⦁ Zou CY, Liu XK, Sang YQ, Wang B, Liang J. Effects of SGLT2 inhibitors on

cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis.

Medicine. 2019 Dec 1;98(49):e18245.

⦁ McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZ, Dagogo-Jack

S, Pratley R, Greenberg M, Wang S, Huyck S, Gantz I. Association of SGLT2

inhibitors with cardiovascular and kidney outcomes in patients with type 2

diabetes: a meta-analysis. JAMA cardiology. 2021 Feb 1;6(2):148-58.

⦁ Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine MJ, Heerspink HL,

Wong MG, Ninomiya T, Wada T, Perkovic V. Effect of SGLT2 inhibitors on

cardiovascular, renal and safety outcomes in patients with type 2 diabetes

mellitus and chronic kidney disease: a systematic review and meta‐

analysis. Diabetes, Obesity and Metabolism. 2019 May;21(5):1237-50.

⦁ Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O,

Kato ET, Cahn A, Furtado RH, Bhatt DL. SGLT2 inhibitors for primary and

secondary prevention of cardiovascular and renal outcomes in type 2

diabetes: a systematic review and meta-analysis of cardiovascular outcome

trials. The Lancet. 2019 Jan 5;393(10166):31-9.

⦁ Jiang Y, Yang P, Fu L, Sun L, Shen W, Wu Q. Comparative cardiovascular

outcomes of SGLT2 inhibitors in type 2 diabetes mellitus: a network meta-

analysis of randomized controlled trials. Frontiers in Endocrinology. 2022

Mar 16;13:802992.

⦁ Giugliano D, Longo M, Scappaticcio L, Bellastella G, Maiorino MI, Esposito

K. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without

type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovascular Diabetology.

Dec;20:1-1.

⦁ Dave CV, Kim SC, Goldfine AB, Glynn RJ, Tong A, Patorno E. Risk of

cardiovascular outcomes in patients with type 2 diabetes after addition of

SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy.

Circulation. 2021 Feb 23;143(8):770-9.

⦁ Qiu M, Ding L, Zhou H. Effects of SGLT2 inhibitors on cardiovascular and

renal outcomes in type 2 diabetes: a meta-analysis with trial sequential

analysis. Medicine. 2021 Mar 12;100(10):e25121.

⦁ Dawwas GK, Smith SM, Park H. Cardiovascular outcomes of sodium

glucose cotransporter‐2 inhibitors in patients with type 2 diabetes.

Diabetes, Obesity and Metabolism. 2019 Jan;21(1):28-36.

⦁ Scheen AJ. Effects of reducing blood pressure on cardiovascular outcomes

and mortality in patients with type 2 diabetes: focus on SGLT2 inhibitors

and EMPA-REG OUTCOME. Diabetes research and clinical practice. 2016

Nov 1;121:204-14.

⦁ Li CX, Liang S, Gao L, Liu H. Cardiovascular outcomes associated with SGLT-

inhibitors versus other glucose-lowering drugs in patients with type 2

diabetes: A real-world systematic review and meta-analysis. PloS one. 2021

Feb 19;16(2):e0244689.

⦁ Longato E, Di Camillo B, Sparacino G, Gubian L, Avogaro A, Fadini GP.

Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2

inhibitors versus GLP-1 receptor agonists in real-life. BMJ Open Diabetes

Research and Care. 2020 Jun 1;8(1):e001451.

⦁ Marilly E, Cottin J, Cabrera N, Cornu C, Boussageon R, Moulin P, Lega JC,

Gueyffier F, Cucherat M, Grenet G. SGLT2 inhibitors in type 2 diabetes: a

systematic review and meta-analysis of cardiovascular outcome trials

balancing their risks and benefits. Diabetologia. 2022 Dec;65(12):2000-10.

⦁ Usman MS, Siddiqi TJ, Anker SD, Bakris GL, Bhatt DL, Filippatos G, Fonarow

GC, Greene SJ, Januzzi Jr JL, Khan MS, Kosiborod MN. Effect of SGLT2

inhibitors on cardiovascular outcomes across various patient populations.

Journal of the American College of Cardiology. 2023 Jun 27;81(25):2377-87.

⦁ Singh AK, Singh R. Cardiovascular outcomes with SGLT-2 inhibitors in

patients with heart failure with or without type 2 diabetes: a systematic

review and meta-analysis of randomized controlled trials. Diabetes &

Metabolic Syndrome: Clinical Research & Reviews. 2021 Jan 1;15(1):351-9.

⦁ Benham JL, Booth JE, Sigal RJ, Daskalopoulou SS, Leung AA, Rabi DM.

Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and

cardiovascular outcomes. IJC Heart & Vasculature. 2021 Apr 1;33:100725.

⦁ Lo KB, Gul F, Ram P, Kluger AY, Tecson KM, McCullough PA, Rangaswami J.

The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in

diabetic patients: a systematic review and meta-analysis. Cardiorenal

medicine. 2020 Jan 2;10(1):1-0.

⦁ Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U,

Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ. Cardiovascular

outcomes with ertugliflozin in type 2 diabetes. New England Journal of

Medicine. 2020 Oct 8;383(15):1425-35.

⦁ Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 inhibitors and

cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study.

Diabetes care. 2016 May 1;39(5):717-25.

⦁ d'Emden M, Amerena J, Deed G, Pollock C, Cooper ME. SGLT2 inhibitors

with cardiovascular benefits: Transforming clinical care in Type 2 diabetes

mellitus. Diabetes research and clinical practice. 2018 Feb 1;136:23-31.

Downloads

Published

06/30/2024

Issue

Section

Research Articles

Categories

How to Cite

1.
Ahmad H, Saleem S, Tahiri H, Nisar S, Ullah safi, Bilal M. Investigating the impact of SGLT2 Inhibitors on Cardiovascular Outcomes  in Patients with Type 2 Diabetes. IRABCS [Internet]. 2024 Jun. 30 [cited 2024 Jul. 20];2(1):80-4. Available from: https://irabcs.com/ojs/article/view/40

Similar Articles

1-10 of 38

You may also start an advanced similarity search for this article.